Stem Cells
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

First published online August 18, 2005
Stem Cells Vol. 24 No. 2 February 2006, pp. 462 -471
doi:10.1634/stemcells.2004-0331; www.StemCells.com
© 2006 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2004-0331v1
24/2/462    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sotiropoulou, P. A.
Right arrow Articles by Papamichail, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sotiropoulou, P. A.
Right arrow Articles by Papamichail, M.

TECHNOLOGY DEVELOPMENT

Characterization of the Optimal Culture Conditions for Clinical Scale Production of Human Mesenchymal Stem Cells

Panagiota A. Sotiropoulou, Sonia A. Perez, Maria Salagianni, Constantin N. Baxevanis, Michael Papamichail

Cancer Immunology and Immunotherapy Center, Saint Savas Hospital, Athens, Greece

Key Words. Mesenchymal stem cells • Clinical trials • Expansion • Culture conditions

Correspondence: Panagiota A. Sotiropoulou, Ph.D., Cancer Immunology and Immunotherapy Center, Saint Savas Hospital, 171 Alexandras Avenue, 115 22, Athens, Greece. Telephone: 30-210-6409462; Fax: 30-210-6409516; e-mail: sotiropoulou{at}ciic.gr

Mesenchymal stem cells (MSCs) are multipotent cells defined by multilineage potential, ease to gene modification, and immunosuppressive ability, thus holding promise for tissue engineering, gene therapy, and immunotherapy. They exhibit a unique in vitro expansion capacity, which, however, does not compensate for the very low percentage in their niches given the vast numbers of cells required for the relative studies. Taking into consideration the lack of a uniform approach for MSC isolation and expansion, we attempted in this study, by comparing various culture conditions, to identify the optimal protocol for the large-scale production of MSCs while maintaining their multilineage and immunosuppressive capacities. Our data indicate that, apart from the quality of fetal calf serum, other culture parameters, including basal medium, glucose concentration, stable glutamine, bone marrow mononuclear cell plating density, MSC passaging density, and plastic surface quality, affect the final outcome. Furthermore, the use of basic fi-broblast growth factor (bFGF), the most common growth supplement in MSC culture media, greatly increases the proliferation rate but also upregulates HLA-class I and induces low HLA-DR expression. However, not only does this upregulation not elicit significant in vitro allogeneic T cell responses, but also bFGF-cultured MSCs exhibit enhanced in vivo immunosuppressive potential. Besides, addition of bFGF affects MSC multilineage differentiation capacity, favoring differentiation toward the osteogenic lineage and limiting neurogenic potential. In conclusion, in this report we define the optimal culture conditions for the successful isolation and expansion of human MSCs in high numbers for subsequent cellular therapeutic approaches.




This article has been cited by other articles:


Home page
 Stem CellsHome page
D. A. Rider, C. Dombrowski, A. A. Sawyer, G. H. B. Ng, D. Leong, D. W. Hutmacher, V. Nurcombe, and S. M. Cool
Autocrine Fibroblast Growth Factor 2 Increases the Multipotentiality of Human Adipose-Derived Mesenchymal Stem Cells
Stem Cells, June 1, 2008; 26(6): 1598 - 1608.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
J Larghero, D Farge, A Braccini, S Lecourt, A Scherberich, E Fois, F Verrecchia, T Daikeler, E Gluckman, A Tyndall, et al.
Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis
Ann Rheum Dis, April 1, 2008; 67(4): 443 - 449.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
N. Sessarego, A. Parodi, M. Podesta, F. Benvenuto, M. Mogni, V. Raviolo, M. Lituania, A. Kunkl, G. Ferlazzo, F. D. Bricarelli, et al.
Multipotent mesenchymal stromal cells from amniotic fluid: solid perspectives for clinical application
Haematologica, March 1, 2008; 93(3): 339 - 346.
[Abstract] [Full Text] [PDF]

Home page
 J BiochemHome page
M. J. Go, C. Takenaka, and H. Ohgushi
Effect of Forced Expression of Basic Fibroblast Growth Factor in Human Bone Marrow-Derived Mesenchymal Stromal Cells
J. Biochem., December 1, 2007; 142(6): 741 - 748.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
F. Locatelli, R. Maccario, and F. Frassoni
Mesenchymal stromal cells, from indifferent spectators to principal actors. Are we going to witness a revolution in the scenario of allograft and immune-mediated disorders?
Haematologica, July 1, 2007; 92(7): 872 - 877.
[Full Text] [PDF]

Home page
 Stem CellsHome page
F. Mannello and G. A. Tonti
Concise Review: No Breakthroughs for Human Mesenchymal and Embryonic Stem Cell Culture: Conditioned Medium, Feeder Layer, or Feeder-Free; Medium with Fetal Calf Serum, Human Serum, or Enriched Plasma; Serum-Free, Serum Replacement Nonconditioned Medium, or Ad Hoc Formula? All That Glitters Is Not Gold!
Stem Cells, July 1, 2007; 25(7): 1603 - 1609.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
A. Kocaoemer, S. Kern, H. Kluter, and K. Bieback
Human AB Serum and Thrombin-Activated Platelet-Rich Plasma Are Suitable Alternatives to Fetal Calf Serum for the Expansion of Mesenchymal Stem Cells from Adipose Tissue
Stem Cells, May 1, 2007; 25(5): 1270 - 1278.
[Abstract] [Full Text] [PDF]

Home page
 EuropaceHome page
D. G. Katritsis, P. Sotiropoulou, E. Giazitzoglou, E. Karvouni, and M. Papamichail
Electrophysiological effects of intracoronary transplantation of autologous mesenchymal and endothelial progenitor cells
Europace, March 1, 2007; 9(3): 167 - 171.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
A. Heiskanen, T. Satomaa, S. Tiitinen, A. Laitinen, S. Mannelin, U. Impola, M. Mikkola, C. Olsson, H. Miller-Podraza, M. Blomqvist, et al.
N-Glycolylneuraminic Acid Xenoantigen Contamination of Human Embryonic and Mesenchymal Stem Cells Is Substantially Reversible
Stem Cells, January 1, 2007; 25(1): 197 - 202.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
P. Tropel, N. Platet, J.-C. Platel, D. Noel, M. Albrieux, A.-L. Benabid, and F. Berger
Functional Neuronal Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells
Stem Cells, December 1, 2006; 24(12): 2868 - 2876.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
C. A. Gregory, E. Reyes, M. J. Whitney, and J. L. Spees
Enhanced Engraftment of Mesenchymal Stem Cells in a Cutaneous Wound Model by Culture in Allogenic Species-Specific Serum and Administration in Fibrin Constructs
Stem Cells, October 1, 2006; 24(10): 2232 - 2243.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
I. Dimarakis and N. Levicar
Cell Culture Medium Composition and Translational Adult Bone Marrow-Derived Stem Cell Research
Stem Cells, May 1, 2006; 24(5): 1407 - 1408.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS

Copyright © 2006 by AlphaMed Press.